Cluster Randomised Non-inferiority Trial Comparing Malaria Incidence When Implementing R21/Matrix-M Synchronized With Seasonal Malaria Chemoprevention Distribution Versus R21/Matrix-M Given Routinely Through the EPI in Two Health Districts in Chad (CoSAV-R21)

This is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering the R21/MM malaria vaccine, synchronized within a seasonal malaria chemoprevention (SMC) campaign, among children living in areas of high seasonal malaria transmission.
In this study, a cluster is defined as the catchment area of a primary care health centre. In Chad, each catchment area is known as a 'zone of responsibility' (French: Zone de Responsibilité' [ZR]).
Twenty-six (26) of the total 27 ZRs in the districts of Moïssala and Dembo will be randomized in a 1:1 ratio to receive a 4-dose (3 primary doses + 1 booster) R21/MM schedule either (1) integrated into the routine EPI vaccination program (the "Routine" control arm), or (2) synchronized with an annual seasonal malaria chemoprevention (SMC) campaign (the "Synchronized" intervention arm).
Malaria incidence: R21/MM effectiveness will be assessed using the incidence of biologically confirmed clinical malaria (trial primary endpoint). The incidence of clinical malaria will be determined through enhanced surveillance of malaria cases in health centres and hospitals over a 17-month period (August 2025 - December 2026).
Coverage surveys: Cross-sectional surveys (cluster sampling) will be carried out to measure R21/MM vaccine coverage, SMC coverage, coverage of other malaria prevention measures, and coverage of other EPI vaccines.
Nested case-control study: A sub-sample of children admitted to Moïssala District Hospital with severe clinical malaria will be offered the opportunity to participate in a nested case-control study designed to estimate the individual protective efficacy of R21/MM against severe malaria.

开始日期2025-07-02

申办/合作机构

Epicentre Technologies Corp.

[+1]

NCT06860178

/ Recruiting临床4期

Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa

This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the eﬀectiveness and real-life impact of a novel integrated delivery strategy of the R21 malaria vaccine alongside SMC among children in areas with highly seasonal malaria transmission. In this study, a cluster is defined as the catchment area of a health centre. Clusters will be randomised to receive either year-round age-based routine EPI vaccination for children aged 5-36 months ("Routine EPI Vaccination") in Burkina Faso or an annual campaign of the 3-dose primary series in children aged 5-36 months prior to the malaria season and SMC delivery (''Routine Pre-SMC vaccination'') in Mali versus an annual campaign of the 3-dose primary series aligned with SMC distribution in children aged 3-59 months ("Integrated SMC Vaccination") in each country. Eﬀectiveness will be assessed in terms of clinical malaria, vaccine coverage, acceptability, feasibility, and cost-eﬀectiveness.
Malaria incidence will be determined using routine surveillance activities for clinical malaria detection and reporting in each country. Cross-sectional surveys will be conducted to determine the prevalence of parasitaemia in the communities. In addition, the acceptability, feasibility, coverage and cost-effectiveness of the different delivery systems of R21/Matrix-M will be assessed.

开始日期2025-06-10

申办/合作机构

Epicentre Technologies Corp.

[+2]

PACTR202502765006598

/ Suspended临床4期

Integrating malaria vaccine with seasonal malaria chemoprevention in West Africa

开始日期2025-04-01

申办/合作机构

Epicentre Technologies Corp.

100 项与 Illumina, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Illumina, Inc. 相关的专利（医药）

登录后查看更多信息

768

项与 Illumina, Inc. 相关的文献（医药）

2025-09-01·JOURNAL OF MOLECULAR DIAGNOSTICS

Cell-Free DNA, Tumor Molecular Concordance, and Clinical Correlates of Patients with Cancer Treated in a Large Community Health Care Network

Article

作者: Schumacher, Philip E ; Zaidi, Ali H ; Hilton, Christie J ; Ercolano, Lisa B ; Petrosko, Patti ; Nakayama, John ; Lam, Tuong L ; Gallo, Phillip H ; LaFramboise, William A ; Bartlett, David L ; Patel, Sefali ; Barr, Robin M ; Carja, Oana ; Taylor, Katherine M ; Schwartz, Russell ; Allen, Casey J ; Rachman, Thomas ; Dalton, Emily ; Bapat, Bella ; Wagner, Patrick L ; Gil, Louis ; Kharoud, Harmeet K

Blood collection, plasma processing, and cell-free DNA (cfDNA) purification were optimized to capture circulating tumor DNA without blood cell background DNA among 874 patients with cancer. cfDNA comprised predominantly mononucleosomal fragments [n = 874; mean (x¯) ± SD = 166 ± 5 bp] that generated comparably sized sequencing reads (x¯ ± SD = 162 ± 25 bp). Despite a vast range of cfDNA concentrations (0.50 to 1132.9 ng/mL) across 21 tumor types, matched tumor and blood specimens (n = 430 patients) revealed high concordance for coding (median = 97%) and clinical oncogenic mutations (median = 88% concordance). Therapeutically actionable mutations were identified in 233 patients by both assays, whereas 126 patients had oncogenic mutations without an established pharmacotherapeutic agent. An additional 48 patients (11%) had actionable mutations detected only in cfDNA assays, whereas 23 patients (5%) had mutations in tumor only. Concordance was high in both prevalent (lung, breast, and colon) and rare tumors (appendiceal, sarcoma). Cell-free DNA levels from diagnostic blood specimens were a strong indicator of patient survival duration independent of age, sex, tumor type, and stage, demonstrative of a potentially important role as a prognostic biomarker. Mutations in established oncogenes and tumor suppressors were readily detectable across all tumor types in circulating tumor DNA, indicating a diagnostic role for cfDNA from blood extending beyond the identification of companion therapeutics to patient screening and monitoring.

2025-09-01·JOURNAL OF MOLECULAR DIAGNOSTICS

Cost-Effectiveness Analysis of Comprehensive Genomic Profiling in Patients with Advanced Non–Small-Cell Lung Cancer Using Real-World Data

Article

作者: Peng, Siyang ; Zou, Denise ; Ye, Weicheng ; Spencer, Scott

Cancer treatment costs pose a significant global economic burden. By facilitating treatment plans tailored to the genomic profile of patients' cancer, genomic testing has the potential to reduce health care costs. Using real-world evidence, this study compared the cost-effectiveness of comprehensive genomic profiling (CGP) versus small panel (SP) testing in patients with advanced non-small-cell lung cancer in the United States and Germany. A partitioned survival model was developed to estimate the life years and drug acquisition costs associated with CGP and SP testing in patients receiving matched targeted therapy, matched immunotherapy, or no matched therapy/untreated. Key model parameters were informed by real-world data derived from the Syapse study. Scenario and sensitivity analyses were conducted. CGP improved the average overall survival by 0.10 years compared with SP. CGP was associated with higher health care costs because of a higher percentage of patients receiving targeted therapies. The estimated incremental cost-effectiveness ratio (ICER) of CGP versus SP was $174,782 and $63,158 per life-year gained in the United States and Germany, respectively. Increasing the number of patients receiving treatment decreased the ICERs ($86,826 in the United States and $29,235 in Germany), while switching from immunotherapy plus chemotherapy to chemotherapy alone increased the ICERs ($223,226 in the United States and $83,333 in Germany). Altogether, CGP has the potential to improve patient outcomes and is more cost-effective than SP.

2025-08-19·mSystems

Illumina complete long read assay yields contiguous bacterial genomes from human gut metagenomes

Article

作者: Darling, Aaron E. ; Ying, Kevin ; Statham, Aaron ; Monahan, Leigh G. ; Bhatt, Ami S. ; Truong, Tiffany ; Burke, Catherine M. ; Jaeger, Erich ; Kiguchi, Yuya ; Halpern, Aaron L. ; Bruinsma, Stephen P. ; Schroth, Gary P. ; Maghini, Dylan G.

ABSTRACT:

Metagenomics enables direct investigation of the gene content and potential functions of gut bacteria without isolation and culture. However, metagenome-assembled genomes are often incomplete and have low contiguity due to challenges in assembling repeated genomic elements. Long-read sequencing approaches have successfully yielded circular bacterial genomes directly from metagenomes, but these approaches require high DNA input and can have high error rates. Illumina has recently launched the Illumina Complete Long Read (ICLR) assay, a new approach for generating kilobase-scale reads with low DNA input requirements and high accuracy. Here, we evaluate the performance of ICLR sequencing for gut metagenomics for the first time. We sequenced a microbial mock community and 10 human gut microbiome samples with standard, shotgun 2 × 150 paired-end sequencing, ICLR sequencing, and nanopore long-read sequencing and compared performance in read lengths, assembly contiguity, and bin quality. We find that ICLR human metagenomic assemblies have higher N50 (119.5 ± 24.8 kilobases) than short read assemblies (9.9 ± 4.5 kilobases; P = 0.002), and comparable N50 to nanopore assemblies (91.0 ± 43.8 kilobases; P = 0.32). Additionally, we find that ICLR draft microbial genomes are more complete (94.0% ± 20.6%) than nanopore draft genomes (85.9% ± 23.0%; P≤ 0.001), and that nanopore draft genomes have truncated gene lengths (924.6 ± 114.7 base pairs) relative to ICLR genomes (954.6 ± 71.5 base pairs; P≤ 0.001). Overall, we find that ICLR sequencing is a promising method for the accurate assembly of microbial genomes from gut metagenomes.

IMPORTANCE:

Metagenomic sequencing allows scientists to directly measure the genome content and structure of microbes residing in complex microbial communities. Traditional short-read metagenomic sequencing methods often yield fragmented genomes, whereas advanced long-read sequencing methods improve genome assembly quality but often suffer from high error rates and are logistically limited due to high input requirements. A new method, the Illumina Complete Long Read (ICLR) assay, is capable of generating highly accurate kilobase-scale sequencing reads with minimal input material. To evaluate the utility of ICLR in metagenomic contexts, we applied short-read, long-read, and ICLR methods to simple and complex microbial communities. We found that ICLR outperforms short-read methods and yields comparable metagenomic assemblies to standard long-read approaches while requiring less input material. Overall, ICLR represents an additional option for assembling complete genomes from complex metagenomes.

1,326

项与 Illumina, Inc. 相关的新闻（医药）

2025-09-05

·DIA资讯

虚拟患者，真实结果：数字孪生如何重塑药物研发 | DIA“Global Forum”中文版精选文章选读

点击上方DIA资讯关注我们 DIA Glaobal Forum中文版文章选读虚拟患者，真实结果：数字孪生如何重塑药物研发作者：Colin Hill 作者单位：Aitia Bio 授权：本文翻译已获作者授权在医学领域，似乎没有比给有需求的患者提供安慰剂更残忍的事情。然而，尽管存在伦理方面的担忧，自20世纪50年代现代临床试验出现以来，所谓的对照组一直是医学进步的基石。没有它，科学界、患者和监管机构将缺乏数据来判断一种新疗法是否优于安慰剂或现有疗法。除了伦理问题，实际操作中事情同样引发诸多难题。细胞和基因疗法等新兴治疗手段为患者带来了令人瞩目的进步，但这些药物只能在大城市的大型医疗中心中使用，使得临床试验招募变得更加困难，更不用说实现患者多元化所面临的挑战，美国食品药品监督管理局（FDA）正通过出台新指南重点解决这个问题。幸运的是，技术发展催生出虚拟患者，或者说数字孪生。它可以用于从发现新候选药物到临床试验开发的各个环节。通过利用新生成的基因组、蛋白质组和临床数据，数字孪生正被用来提高研究结果转化为可行药物靶标的成功率，减少临床试验所需的人数，并用虚拟患者代替安慰剂对照组。数字孪生的演进，从登月计划到分子研究数字孪生并非新兴概念：美国宇航局（NASA）在20世纪60年代就提出了这个想法，并在“阿波罗13号”任务中使用“实物模型”帮助因氧气罐爆炸导致主引擎受损的宇航员。制造业也早已使用数字孪生，通过实体产品对自身的实验和想法进行模拟。例如，联合利华在其肥皂和洗涤剂中运用数字孪生技术减少了90%需要关注的误报。在中国，中信重工利用数字孪生和3D建模来预测设备故障，为其水泥业务提供运营和维护解决方案，节省了30%以上的成本。KINEXON公司借助数字孪生技术使汽车转配速度提高了5%，并显著减少了人为错误和产品召回。但在医疗保健和生物医学领域，数字孪生直到最近才成为，这得益于DNA测序成本的急速下降下降⸺从2003年人类基因组计划花费27亿美元，降低到2023年Illumina公司的200美元，同时可以快速且低成本生成每个基因产物的高通量分子数据（多组学数据），以及计算能力的指数级增长。随着更多可用的遗传和多组学数据，以及在超级计算机上运行的生成性因果人工智能能够快速筛选信息，科学家们现在可以先在计算机中进行模拟（ i nsilico），再进行活体动物试验（通常使用小鼠）（in vivo），最后在人体中开展临床试验。与现实世界中可能需要数年时间来确定一种实验药物是否安全有效不同，借助数字孪生，研究人员可以在数小时或数天内测试数十亿中猜想。监管机构正致力于指定新的政策和指南，以允许在药物研发和临床试验中使用数字孪生。FDA发布了一份文件，详细说明了该技术的当前和未来的用途，表示其有潜力“以多种方式推动药物研发，包括助力更快地将安全有效的药物带给患者；扩大药物的可及性，从而促进健康公平性。”此外，FDA表示，数字孪生“可能提供一份全面、纵向且经计算生成的临床记录，描述特定参与者接受安慰剂可能出现的情况。”欧洲药品管理局（EMA）也已开始探索和实施纳入数字孪生的框架，从其更广泛的“人工智能行动计划”开始，对数字孪生在二期和三期临床试验中的应用给出了积极的资质认定意见。EMA的这一举措标志着监管机构首次认可基于机器学习的方法应用于关键临床试验。制药公司和人工智能（AI）公司之间的合作已经初见成效。AI公司Unlearn与强生公司合作开展的研究表明，在三期阿尔茨海默症试验中，数字孪生可将对照组的规模减少多达33%。临床开发数据分析公司Phesi在6月证实，AI驱动的数字孪生能够在慢性移植物抗宿主病试验中取代标准治疗的对照组。 Phesi的首席执行官兼创始人Gen Li博士在于2024年9月发表于《应用临床试验》杂志的一篇文章中写道，“数字孪生技术使申办方在启动临床试验之前‘接触患者’，通过使试验设计和目标患者群体更好地契合，避免代价高昂的方案修正；并提高商业可行性”。像素取代移液管（Pixels over Pipettes）：推进临床前研究然而，医疗保健领域更大的一场革命，或许源于在药物研发过程中更早地运用数字孪生技术，即决定哪些疗法应进入人体试验的临床前阶段。平均而言，从靶点发现到新药获批大约需要 14 年时间，成本高达 10 亿美元以上，而失败率在 90% - 95% 之间。鉴于这些情况，生物制药公司一直在探寻新的、更有效的方法来提高成功率。近年来，生物制药行业临床开发成功率出现令人担忧的下滑，获批上市的药物越来越少。疾病生物学的复杂性和靶标选择不当等因素，导致了较高的淘汰率。最近一份报告指出，一种新的一期临床试验药物获批的平均可能性仅为令人沮丧的6.7%。通过创建生物系统的虚拟模型，研究人员能够更好地预测哪些候选药物可能在临床研究中取得成果，最终减少对临床前研究的依赖。这并非只是理论设想；一项对人工智能发现的药物的分析表明，这些疗法在一期临床试验中的成功率 “显著” 高于传统方式发现的疗法，达到 80% - 90% 。如果这些成果在后续阶段可以依然保持，这将使制药行业现有的药物研发能力几乎翻倍。在研发领域，数字孪生可用于创建疾病的计算机模型，使科学家能够基于人体生物学进行数十亿次虚拟实验。这些数字孪生模型是通过对驱动临床结果的已知及先前未知的基因与分子相互作用进行逆向工程构建而成。其关键区别在于使用因果人工智能：超越药物研发中传统使用的模式识别和相关性分析，去寻找真正的因果联系。有关因果人工智能的专题报道，可参见《全球论坛》2024 年 10 月刊。这种方法的一个典型例子是在亨廷顿病研究中对数字孪生的应用。尽管研究人员早在 1983 年就确定了导致该病的基因，但有效的治疗方法却寥寥无几。为解决这一问题，研究人员利用一些规模最大的亨廷顿病研究数据创建了该疾病的数字孪生模型，生成的模型包含约 23000 个节点和 530 万种交互作用。借助这个复杂的模型，研究人员得以确定一个影响亨廷顿病认知和运动功能的新靶点。一种抑制该靶点的小分子候选药物有望减缓运动症状的进展，同时不影响正常的细胞代谢。这个结合了人类多组学数据、因果人工智能以及临床前和临床数据的数字孪生平台，也正应用于一系列肿瘤学和神经学疾病的研究，包括阿尔茨海默病、帕金森病、胰腺癌、前列腺癌和多发性骨髓瘤。 “目前，数字孪生方法最大的应用机会在于药物研发的临床前及生产环节，因为只有约 0.1% 的药物化合物能够进入人体临床试验阶段，所以提高这一比例是最大的投资回报点。”Medable 公司数字成果与治疗领域副总裁Musaddiq Khan说道，Medable 是一家为临床试验提供技术平台的公司。“随着我们能够从不同渠道收集并研究更多数据 ——通过可穿戴设备、健康记录、基因组数据以及历史数据集——我们将更有能力在数字孪生试验参与者中模拟特定途径和系统。” Khan补充说：“同样至关重要的是，研究人员不仅要做好收集相关数据的准备，还要确保使用数字孪生技术的操作优势，并且保证试验设计合理。此外，还有伦理方面的考量。我们如何验证预测结果？如果两个模型表现不同该怎么办？这就引发了关于如何在行业内进行标准化以便获得适当审批的更多问题。数字孪生为改善我们的研究方式提供了巨大潜力，但也需要进行很多前期思考。” 比特、字节和突破（Bits, Bytes, and Breakthroughs）：绘制数字生物未来蓝图- 行业专家认为，这项技术在变革药物研发方面潜力巨大。随着生物数据的数量和种类呈指数级增长——诸如单细胞组学等进展带来了更为详尽的认知——且人工智能和计算能力也同步提升，预计会出现更精准、更具预测性和解释性的数字孪生模型。数字孪生技术的更广泛应用，有望降低长期困扰制药行业的高淘汰率。在药物研发早期，数字孪生有助于识别更有潜力的药物靶点以及能够抑制这些靶点的优化化合物。在临床开发阶段，数字孪生可通过筛选出会对药物产生反应的患者来完善试验设计，还有助于优化试验方案、预测入组率并预估完成时间。通过模拟患者反应，数字孪生或许还能促成更有效的适应性试验设计，使研究人员能够实时做出基于数据的决策。这可能会带来更高效的试验，减少对患者数量和资源的需求。它们甚至有可能减少或消除临床试验中对安慰剂组的需求。“要实现数字孪生的广泛应用并产生变革性影响，需要全行业的协作与数据共享，” Khan说道，“我们正朝着正确的方向前进，尤其是借助去中心化试验证据生成平台和人工智能驱动的工具。我预计这一领域会取得重大进展，但人体和所研究药物的复杂性意味着这并非易事。” 随着该领域的持续发展，科技公司、药物研发企业、监管机构和医疗服务提供商之间的合作至关重要。通过整合多样的专业知识和数据来源，行业能够朝着数字孪生成为药物研发过程不可或缺一部分的未来迈进，这有可能带来更有效的治疗方法、降低研发成本、缩短药物上市时间，最终为患者带来更好的治疗效果。阅读DIA Global Forum中文版全部文章，请扫描二维码加入优享Plus。优享Plus可直接登录网站查看完整版 SETP 1 进入优享Plus学员登录优惠专区 http://kc.dianow.cn/ STEP 2 使用学员账号登录，从“课程中心”进入，查看您Plus权益中的DIA“Global Forum中文版”完整版阅读 DIA中国近期会议/培训 2026 May 14-17 ● 2026 DIA药物信息大会暨展览会 ► 点击阅读 Sep 18-19 ● 2025 DIA 第六届M4/M8全球与中国申报实战经验研讨班 ► 点击阅读 Sep 26-27 ●2025 DIA 大湾区专题会议暨第二届药品监管科学澳门论坛 ► 点击阅读 Oct 21-22 ●2025 DIA 从中国出发-全球影响力由此开启 DIA北京论坛 ► 点击阅读 Oct 23-25 ● 2025 DIA 药物研发定量科学论坛（QSF） ► 点击阅读 Nov 1 ● AI在医药研发中的合规体系构建与策略设计 ► 点击阅读 Nov 14-15 ● 高级统计学贝叶斯早期创新临床试验(Ib+II)线下班 ► 点击阅读 Nov 20-21 ● 2025药物警戒科学和风险管理论坛 ► 点击阅读关于DIA DIA是一个全球化、跨学科的国际性学术平台，在中立的环境中，融合医药研发领域全行业的意见领袖，探讨当前研发的技术问题，提升专业能力，以及催化行业共识，在全球医药研发领域享有很高的声誉。扫码关注我们微信号｜DIA资讯长按识别左侧二维码即可关注我们努力为你提供有内容的内容。

2025-09-04

·Firstwordpharma

Illumina launches Protein Prep to put proteomics at the centre of drug discovery

Illumina has launched Protein Prep, a sequencing-based assay that measures almost 9,500 human proteins in a single run. The company said the platform is aimed at scaling up proteomic research and generating insights that genomics alone cannot deliver.Protein Prep uses SomaLogic’s aptamer chemistry on Illumina’s NovaSeq sequencers, with DRAGEN software handling downstream analysis. Results can be turned around in about two and a half days with roughly four hours of hands-on time, a shift Illumina said makes it possible to carry out high-throughput proteomics at a scale not previously practical. Older assays typically measured only a few dozen proteins at a time.The system has been tested in an early-access programme with nearly 40 groups that processed more than 36,000 samples. Genomics England reported a 7.5% improvement in diagnostic yield when Protein Prep was added to its rare disease work. At the University of Colorado Anschutz Medical Campus, researchers are using the assay to study why rare melanomas are less responsive to immunotherapy.The launch comes shortly after Illumina agreed to acquire SomaLogic for $350 million in a deal expected to close in 2026. The takeover will bring SomaLogic’s Colorado operations under Illumina’s control and tie the chemistry behind Protein Prep more closely to its sequencing portfolio.While traditional proteomic tools have offered a narrower but straightforward view of cellular biology, Illumina is betting that broader assays will become the default for research that demands depth and scale. For pharmaceutical companies, that shift could alter how drug targets are validated and how biomarker strategies are built into clinical programmes.Illumina has followed a similar playbook in oncology, where it has steadily expanded its tumour profiling assays to cover more markers, integrated analyses, and reduced turnaround time. Protein Prep now extends that philosophy into proteomics, positioning high-plex protein analysis as part of routine large-scale studies rather than a specialised add-on.Whether researchers and clinicians adopt broad-scale protein measurement as readily as they did genomics is not yet clear. But with early users reporting gains in diagnostic yield and new opportunities in drug discovery, Illumina is moving to establish proteomics as a core element of how disease is studied and how therapies are developed.

并购蛋白降解靶向嵌合体

2025-09-03

·FierceBiotech

Illumina begins rolling out protein prep platform ahead of SomaLogic buy

According to Illumina, Protein Prep is capable of measuring up to 9,500 unique human protein targets when run on its NovaSeq hardware using SomaLogic’s SOMAmer reagents. \n Illumina has begun rolling out its protein research platform, powered in part by tech from SomaLogic, which the DNA sequencing giant signed up to buy out a few months ago after years of collaborative work.That $425 million acquisition deal with SomaLogic’s corporate owner Standard BioTools, first announced in June, has yet to be finalized—but that’s not stopping the two companies from moving forward with their proteomics research assays. Dubbed Illumina Protein Prep, the system was first piloted last year with nearly 40 research teams before expanding to a limited early access program this past spring. After being used to process tens of thousands of samples, it is now being made available more broadly. According to Illumina, the platform is capable of measuring up to 9,500 unique human protein targets in a single experiment, when run on its NovaSeq hardware using SomaLogic’s SOMAmer reagents, with the goal of allowing researchers to incorporate proteomics into large-scale genomics studies and projects to uncover new biomarkers.“NGS-based proteomics provides critical speed, accuracy, reproducibility, and scalability to power large studies and accelerate the drug discovery pipeline for our ecosystem partners in biopharma,” Illumina’s chief technology officer, Steve Barnard, Ph.D., said in a statement. “Proteomics is essential to advancing our understanding of disease and is a central pillar of multiomics. Illumina Protein Prep will help deliver multiomics at scale to transform biologic discovery,” Barnard added. Illumina cited the work of Genomics England and its 100,000 Genomes Project, which it said has been using Protein Prep to profile more than 7,800 participants in the study’s rare disease cohort. That included a pilot to increase diagnostic yield, starting with screenings of 500 samples.“Until now, proteomics has been considered as a standalone research test, and what this study shows is it will have a much bigger clinical impact on both rare and common diseases,” said Matthew Brown, M.D., Genomics England’s chief scientific officer.At the same time, Illumina has been working with U.K. Biobank and biopharma developers including GSK, Johnson & Johnson and Novartis as well as Standard BioTools to analyze the proteins of another 50,000 samples.The deal to acquire SomaLogic includes $350 million upfront plus up to $75 million in performance-based milestones and royalties linked to library prep kit sales. Standard BioTools will also retain commercialization rights to some SOMAmer reagents, which can be used in its SomaScan platform as well as in ELISA tests and other research workflows.SomaLogic counts about 250 worldwide employees and maintains CLIA- and CAP-certified lab space in Boulder, Colorado. Illumina said in its announcement that it expects the business to become profitable in 2027, after the deal closes in the first half of 2026. Earlier this year, Illumina also raised the curtain on its plans in spatial transcriptomics, with a new multimodal software platform running on its NextSeq and NovaSeq hardware. Called Illumina Connected Multiomics, it will link genomic, proteomic, transcriptomic, epigenetic and single-cell analyses within the same platform.